Optimizing Communication and Overcoming Roadblocks in T2D Optimizing Communication and Overcoming Roadblocks in T2D
Endocrinologist Marie McDonnell discusses with her long-term patient Lorraine Kalp effective communication strategies used in overcoming roadblocks encountered in management of type 2 diabetes.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 18, 2024 Category: Consumer Health News Tags: Diabetes & Endocrinology Care Cues Source Type: news
Type 2 diabetes test may be inaccurate for people with South Asian heritage
A gene variant found almost exclusively in people of South Asian heritage affects the accuracy of the standard HbA1c test used to diagnose and monitor type 2 diabetes. Research, presented at the Diabetes UK Professional Conference 2024, showed that nearly eight per cent of people of South Asian heritage carry the gene, suggesting that blood sugar levels... Read moreThe post Type 2 diabetes test may be inaccurate for people with South Asian heritage appeared first on Nursing in Practice. (Source: Nursing in Practice)
Source: Nursing in Practice - April 18, 2024 Category: Nursing Authors: Carolyn Scott Tags: Diabetes HbA1c test Health inequality Source Type: news
Forget Ozempic, try the temporary 'gut liner' which makes you feel full quicker! 60cm sleeve inserted into the stomach through the mouth 'helps you keep weight off two years after it's removed'
Research presented at the Diabetes UK conference in London found it helped people with type 2 diabetes maintain lower blood sugar levels, reducing the risk of serious complications. (Source: the Mail online | Health)
Source: the Mail online | Health - April 17, 2024 Category: Consumer Health News Source Type: news
Some Gut Bugs May Help Lower Your Cholesterol
WEDNESDAY, April 17, 2024 -- Changes in gut bacteria have been linked to a variety of different diseases, including type 2 diabetes, obesity and inflammatory bowel disease.Now, a new study indicates that gut bacteria also might play a role in a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 17, 2024 Category: General Medicine Source Type: news
Brenzavvy vs Farxiga for T2D; PFAS in Seafood; 100 Deaths Linked to GLP-1 Drugs?
(MedPage Today) -- Bexagliflozin (Brenzavvy) and dapagliflozin (Farxiga) induced similar HbA1c reductions over 24 weeks in a head-to-head phase III trial of the SGLT2 inhibitors in Chinese adults with type 2 diabetes on metformin. (Journal of Diabetes... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - April 16, 2024 Category: Endocrinology Source Type: news
Ozempic Hurts the Fight Against Eating Disorders
It’s impossible to escape the soaring popularity of Ozempic and similar drugs these days—daily headlines, celebrity “success” stories, and apparent ease in procuring prescriptions (even Costco sells them now) abound. But the cumulative effect of all of this has many experts in the eating disorder field worried about how this might affect their patients. This makes sense—even for those without eating disorders, these drugs can feel both triggering and enticing. After all, research tells us about 90% of women are dissatisfied with their bodies. This sounds like a quick fix.
[time-brightcove not-...
Source: TIME: Health - April 16, 2024 Category: Consumer Health News Authors: Cole Kazdin Tags: Uncategorized freelance Source Type: news
How big is the GLP-1 market? Exploring its growth potential By
GLP-1 receptor agonists are changing the way chronic conditions like type 2 diabetes are managed, but they have also been approved in the United States to treat obesity, resulting in investors assessing the various outcomes if they become more widely adopted. But how big is the market for these…#glp1 #goldmansachs #fatimacodystanford #glp1s #mit #jonathangruber #novonordiskas #medicare #goldman #biotech (Source: Reuters: Health)
Source: Reuters: Health - April 15, 2024 Category: Consumer Health News Source Type: news
Novo Nordisk Arms Wegovy to Be a Triple Threat
Ozempic usage for weight loss has gone viral, making it the highest revenue-generating drug for Novo Nordisk AV/S NYSE: NVO. Originally purposed for Type 2 diabetes, the skyrocketing off-label use for weight loss led Novo to create Wegovy, a stronger version of Ozempic (generic name: semaglutide)…#novonordiskavsnyse #nvo #novo #ozempic #glp1 #elylillyco #lly #novonordisk #ejectionfraction #bmi (Source: Reuters: Health)
Source: Reuters: Health - April 15, 2024 Category: Consumer Health News Source Type: news
Childhood maltreatment and the risk of impaired glucose metabolism or type 2 diabetes in young adults: findings from the Lifelines Cohort Study - Desch ênes SS, Nearchou F, McInerney A, Schmitz N, Pouwer F, Nouwen A.
We examined the associations between childhood maltreatment and the risk of impaired glucose metabolism (IGM) or type 2 diabetes (T2D) in young adults aged 18-35. Participants (N = 8506) from the Lifelines Cohort Study without IGM or diabetes at baseline (... (Source: SafetyLit)
Source: SafetyLit - April 15, 2024 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
The effects of vibrating shoe insoles on standing balance, walking, and ankle-foot muscle activity in adults with diabetic peripheral neuropathy - Hatton AL, Chatfield MD, Cattagni T, Vicenzino B.
BACKGROUND: Peripheral neuropathy is one of the most common complications of type 2 diabetes, which can lead to impaired balance and walking. Innovative footwear devices designed to stimulate foot sensory receptors, such as vibrating insoles, could offer a... (Source: SafetyLit)
Source: SafetyLit - April 15, 2024 Category: International Medicine & Public Health Tags: Engineering, Physics, Structural Soundness and Failure Source Type: news
Diabetes drug shows potential in treating Parkinson ’s disease
A medicine for type 2 diabetes may slow the progression of the symptoms of Parkinson’s disease, research has suggested. Investigators evaluating the glucagon-like peptide 1 receptor agonist (GLP-1 RA) lixisenatide reported less progression of motor disability over a 12-month period in patients taking the drug compared with placebo. But writing in the New England Journal of Medicine, they... Read moreThe post Diabetes drug shows potential in treating Parkinson’s disease appeared first on Nursing in Practice. (Source: Nursing in Practice)
Source: Nursing in Practice - April 12, 2024 Category: Nursing Authors: Megan Ford Tags: Clinical Diabetes Latest news Source Type: news
This outdated diabetes drug still has something to offer
Thiazolidinediones (TZDs) are a class of drug that can be used to treat type 2 diabetes by reversing insulin resistance, one of the main hallmarks of the disease. While TZDs were extremely popular in the 1990’s and early 2000’s, they have fallen out of use among physicians in recent decades because they were discovered to cause unwanted side effects, including weight gain and excess fluid accumulation in body tissues. (Source: World Pharma News)
Source: World Pharma News - April 11, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Is taking statins making my diabetes worse? Dr Rosemary Leonard reveals answer
A reader with type-2 diabetes is no longer able to control her blood sugar through diet alone and asks the Express GP if statins may be the reason for this (Source: Daily Express - Health)
Source: Daily Express - Health - April 10, 2024 Category: Consumer Health News Source Type: news
America ’ s Growing Birthweight Crisis
Americans are increasingly at risk of having lower incomes, poorer health, and a worse shot at opportunity even before they are born. More babies are now born with low birthweights than in the last 30 years. This has caused growing inequalities that can persist if not properly addressed. In certain parts of the country, that risk may be ten-times greater.
Underweight newborns are at an increased risk of long term health challenges, lower IQ scores, and developmental delays. New data shows that the frequency of this problem is rising with more than 300,000 newborns now experiencing low birthweight. This public hea...
Source: TIME: Health - April 9, 2024 Category: Consumer Health News Authors: Jeremy Ney Tags: Uncategorized freelance Source Type: news
ACC: Semaglutide Beneficial in Obesity-Related Heart Failure, Type 2 Diabetes
TUESDAY, April 9, 2024 -- Semaglutide leads to larger reductions in heart failure-related symptoms and physical limitations among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 9, 2024 Category: Pharmaceuticals Source Type: news
